This is the limited version of the Numerate, Inc. company profile: Join LinkedIn or Sign In to see more information.
Numerate was founded in March 2007 to address the lack of predictability and the high costs, timescales, and rates of attrition associated with novel drug design. Numerate’s proprietary platform designs compounds using accurate in silico models of the important causes of drug success and failure. The approach has been extensively validated and shown to routinely bridge the gap between drug candidate specification and multiple series of novel, potent, selective compounds active in vitro and in vivo.
Numerate partners its drug design capabilities with biotechnology and pharmaceutical companies. The business model is fee-for-success: Numerate is rewarded as the proprietary drug candidates it delivers achieve success in the lab, clinic and market.
Your Connections to Numerate, Inc.
Popular Profiles at Numerate, Inc.
Last edited by CEO at Numerate
1150 Bayhill Drive, Suite 203
San Bruno, CA
94066
United States
| Top Schools |
| Stanford Univ. | 19% |
| Univ. of California, Santa Cruz | 19% |
| Univ. of California, Berkeley | 14% |
|
Estimated based on LinkedIn Data
This LinkedIn Company Profile was created by LinkedIn and is about Numerate, Inc.. This page is not endorsed by or affiliated with Numerate, Inc.. For questions regarding LinkedIn Company Profiles, contact us.
